Charles River Laboratories International, Inc. (CRL)
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Charles River (CRL) signs an agreement with AAVantgarde to produce GMP plasmid DNA for Stargardt's disease program.
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
Investors are optimistic about Charles River (CRL) due to its business performance and strategic buyouts.
Charles River's (CRL) RMS Growth Aids Amid FX Headwind
Charles River (CRL) broadens the scope of its products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Inks CDMO Deal With Gates Institutes
Charles River (CRL) signs a lentiviral vector contract development and manufacturing organization agreement with Gates Institute to help develop chimeric antigen receptor (CAR) T-cell therapies.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
CRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary Duties
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officers of Charles River Laboratories International, Inc. (NYSE:CRL) breached their fiduciary duties to CRL and its shareholders. What can I do?
Charles River (CRL) Partners to Reduce Animal Research Usage
Charles River (CRL) announces the development of non-clinical VCG with Sanofi to reduce the use of animals in research.
Charles River (CRL) Launches Viral Vector Tech Transfer Program
Charles River's (CRL) new Fast Track and Modular frameworks facilitate product development continuity via accelerated process transfer to its viral vector Center of Excellence.
Charles River Laboratories: Fair Valuation Against Fundamentals
The life sciences tools and services industry is projected to grow at the rate of 10.8% per year into 2030, driven by advancements in gene sequencing, chromatography, and AI. Charles River Laboratories is a promising investment in this industry, with consistent earnings growth and strong free cash flow margins. CRL's steady Q1 performance and positive outlook for 2024 indicate potential for growth, particularly in its manufacturing solutions division.
Reasons to Hold Charles River (CRL) in Your Portfolio Now
Investors remain optimistic about Charles River (CRL), owing to its acquisitions, thriving DSA segment and financial stability.
Charles River (CRL) Banks on RMS Growth Amid Competition
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.
